Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus XELOX in gastric/GEJ adenocarcinoma
NCT05008783Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Sep 2021; status: completed.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05008783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008783.